Daily Sepsis Research Analysis
Analyzed 22 papers and selected 3 impactful papers.
Summary
Mechanistic studies advance our understanding of organ injury in sepsis by identifying actionable pathways: DTX2-driven K27-linked ubiquitination of TfR1 limits ferroptosis in septic cardiomyopathy; thromboxane receptor signaling in dendritic cells curbs S100A8/A9-mediated neutrophil recruitment; and CCL4 drives inflammatory and fibrotic responses in septic acute kidney injury via STAT3. These targets point toward immunometabolic and chemokine-pathway interventions.
Research Themes
- Ferroptosis and iron metabolism in sepsis-induced organ injury
- Immune regulation via dendritic cell-thromboxane receptor signaling
- Chemokine-driven renal inflammation and fibrosis (CCL4–STAT3 axis)
Selected Articles
1. Deltex E3 ubiquitin ligase 2 prevents sepsis-induced myocardial injury through degrading TfR1 via promoting K27-linked ubiquitination.
DTX2 safeguards the septic heart by promoting K27-linked ubiquitination and degradation of TfR1, thereby limiting iron overload and ferroptosis. Loss of Dtx2 worsened myocardial injury, while cardiac Dtx2 overexpression and ferroptosis inhibition were protective.
Impact: Reveals a mechanistic DTX2–TfR1–ferroptosis axis in septic cardiomyopathy and identifies ubiquitination-based iron control as a therapeutic lever. High translational potential for ferroptosis-targeted interventions.
Clinical Implications: Supports exploring ferroptosis inhibitors, TfR1 modulation, or strategies that enhance DTX2 function as candidate therapies for septic cardiomyopathy. May guide biomarker development around iron handling pathways.
Key Findings
- DTX2 expression increased in septic patients, mice, and LPS-stimulated cardiomyocytes.
- Dtx2 deficiency aggravated myocardial hypertrophy, fibrosis, ferroptosis, and mitochondrial dysfunction in sepsis.
- Cardiac-specific Dtx2 overexpression improved cardiac function in vivo.
- DTX2 directly interacted with TfR1 and mediated K27-linked ubiquitination at lysine 39, promoting TfR1 degradation and regulating iron metabolism.
- Ferroptosis inhibition or TfR1 silencing counteracted injury and ferroptosis in Dtx2-deficient settings.
Methodological Strengths
- Multimodal validation across patient samples, murine sepsis models, and in vitro cardiomyocytes.
- Mechanistic dissection including gain-/loss-of-function genetics and site-specific ubiquitination mapping.
Limitations
- Preclinical study without interventional human data; translational efficacy remains unproven.
- Potential off-target and tissue-specific effects of modulating DTX2–TfR1 not fully characterized.
Future Directions: Assess pharmacologic modulation of DTX2–TfR1 and ferroptosis in large-animal models and early-phase clinical trials; develop biomarkers of iron handling to stratify patients.
Sepsis, a life-threatening systemic inflammatory condition, frequently leads to myocardial injury-a complication for which current therapeutic strategies demonstrate limited efficacy. Here, we explored the potential role and therapeutic implications of Deltex E3 ubiquitin ligase 2 (DTX2) in sepsis-induced myocardial injury. Our results demonstrated that DTX2 expression was significantly upregulated in septic patients, mice models, and lipopolysaccharide (LPS)-stimulated cardiomyocytes. Notably, Dtx2 deficiency markedly aggravated sepsis-induced myocardial hypertrophy, fibrosis, ferroptosis, and mitochondrial dysfunction. In contrast, cardiac-specific overexpression of Dtx2 improved cardiac function in vivo, highlighting its protective role in septic cardiomyopathy. Mechanistically, DTX2 was found to directly interact with transferrin receptor 1 (TfR1) through its DTC domain, mediating K27-linked ubiquitination at lysine 39, which facilitated TfR1 degradation and regulated iron metabolism. Importantly, pharmacological inhibition of ferroptosis counteracted the detrimental effects of Dtx2 deficiency in both LPS-challenged cells and mice. Moreover, genetic silencing of TfR1 considerably suppressed ferroptosis and ameliorated myocardial injury in Dtx2 knockout septic mice. The findings indicate that DTX2 exerts protective effects against abnormal iron accumulation and ferroptosis, thereby alleviating myocardial injury induced by sepsis. These insights could have therapeutic implications for patients with reduced DTX2 expression.
2. Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment.
The study links dendritic cell status to sepsis severity and demonstrates that activating thromboxane receptors in DCs suppresses S100A8/A9-driven neutrophil recruitment, ameliorating sepsis. It positions DC–thromboxane signaling as a tractable immunoregulatory axis.
Impact: Defines a prostanoid receptor pathway in DCs that restrains pathological neutrophil trafficking via S100A8/A9, opening a new angle for sepsis immunotherapy.
Clinical Implications: Suggests evaluating TP receptor agonism or S100A8/A9 pathway modulation, and monitoring DC metrics, to personalize immunomodulation in sepsis.
Key Findings
- Dendritic cell depletion negatively correlated with disease severity in patients with sepsis.
- Activation of thromboxane receptors in dendritic cells suppressed S100A8/A9-mediated neutrophil recruitment.
- Modulating DC–thromboxane signaling mitigated sepsis in experimental models (as indicated by the title and abstract context).
Methodological Strengths
- Integration of human clinical correlations with mechanistic pathway interrogation.
- Focus on a specific leukocyte–prostaglandin receptor axis with defined downstream effector (S100A8/A9).
Limitations
- Abstract details on experimental design, sample sizes, and endpoints are incomplete in the provided text.
- Translational feasibility of TP receptor modulation in sepsis requires safety and efficacy evaluation.
Future Directions: Clarify dose, timing, and delivery of TP receptor agonism; evaluate S100A8/A9-targeted strategies; and validate DC metrics as biomarkers in prospective cohorts.
Dendritic cells (DCs) regulate both innate and adaptive immunity during sepsis. Prostaglandins (PGs), small lipid molecules derived from arachidonic acid via COX enzymes, are crucial regulators of immune homeostasis and inflammation. However, their role in sepsis pathogenesis remains poorly defined. In this study, we identified a significant negative correlation between DC depletion and disease severity in patients with sepsis. Thromboxane (TX) A
3. Inhibition of CCL4 prevents renal inflammation and fibrosis in acute kidney injury.
CCL4 drives inflammatory and fibrotic programs in AKI—including septic AKI—via STAT3 signaling. Genetic CCL4 deletion ameliorated kidney dysfunction and injury in vivo and reduced inflammatory signaling in renal tubular cells in vitro, nominating CCL4 as a therapeutic target.
Impact: Identifies a chemokine–STAT3 axis controlling renal injury and fibrosis across ischemic and septic AKI models, supporting CCL4 blockade as a unified strategy.
Clinical Implications: Encourages translational development of CCL4 inhibitors or STAT3-pathway modulators to prevent or treat septic AKI and limit progression to chronic kidney disease.
Key Findings
- CCL4 knockout attenuated kidney dysfunction and structural damage in acute and chronic phases of I/R-induced AKI.
- Inflammatory and fibrotic mediators (IL-1β, IL-6, TNF-α, TGF-β, p-Smad2/3, collagen 1) were reduced in CCL4-deficient AKI mice.
- In LPS-induced septic AKI, CCL4 deficiency improved kidney dysfunction and inflammation.
- CCL4 inhibition in renal tubular cells reduced hypoxia/reperfusion- and LPS-induced inflammatory responses in vitro.
- Exogenous CCL4 promoted cellular inflammation and fibrosis via STAT3 signaling.
Methodological Strengths
- Use of two complementary in vivo AKI models (ischemia/reperfusion and LPS-induced septic AKI) plus in vitro validation.
- Genetic knockout strategy with pathway interrogation (STAT3) strengthens causality.
Limitations
- Preclinical mouse and cell data; human validation is lacking.
- Pharmacologic inhibition parameters (agent, dose, timing) were not defined in vivo.
Future Directions: Advance CCL4/STAT3 pathway inhibitors into large-animal studies and early-phase clinical trials; evaluate combinatorial strategies with current sepsis care.
Acute kidney injury (AKI) is a clinical concern associated with high morbidity and mortality, with ischemia/reperfusion (I/R) and sepsis-induced AKI being particularly prevalent. Chemokine CC motif ligand 4 (CCL4) is a proinflammatory chemokine that is upregulated in kidney diseases. In this study, we explored the role of CCL4 in the pathogenesis of AKI, focusing on its potential to modulate inflammatory and fibrotic responses through the signal transducer and activator of transcription 3 (STAT3) signaling pathway.Mouse models of I/R injury-induced AKI and lipopolysaccharide (LPS)-induced septic AKI were used for in vivo tests, and renal tubular epithelial cells were used for in vitro tests.Genetic knockout of CCL4 attenuated kidney dysfunction and structural damage in both the acute and chronic phases of I/R injury-induced AKI in mice. CCL4 knockout also reduced the levels of inflammatory and fibrotic proteins such as interleukin-1β, interleukin-6, tumor necrosis factor-α, transforming growth factor-β, p-Smad2/3, and collagen 1 in the kidney of AKI mice. In septic AKI mice, CCL4 knockout improved kidney dysfunction and kidney inflammation. In the in vitro experiments, the inhibition of CCL4 using CCL4 siRNA downregulated hypoxia/reperfusion- and LPS-induced inflammation in renal tubular cells. Furthermore, the administration of CCL4 could cause cellular inflammation and fibrosis through the STAT3 signaling pathway. These findings suggest that CCL4 plays a critical role in AKI pathophysiology, particularly in regulating inflammatory and fibrotic processes through STAT3. Our results suggest that targeting CCL4 may provide a novel therapeutic approach to mitigate AKI and prevent its progression to chronic kidney disease.